Eli Lilly and Company reported significant financial growth in its latest quarterly results, with total revenue reaching $22.97 billion for the three months ended June 30, 2026, a 48% increase from $15.56 billion in the same period last year. For the first half of 2026, revenue was $42.77 billion, up 51% from $28.29 billion in the first half of 2025. The company's net income also saw a substantial rise, totaling $7.10 billion for the second quarter, compared to $5.66 billion a year earlier, marking a 25% increase. Earnings per share (EPS) for the quarter were $7.94, up from $6.29, while the six-month EPS rose to $16.19 from $9.35, reflecting a 73% increase.

The growth in revenue was primarily driven by increased sales volumes of key products, particularly Mounjaro and Zepbound, which together accounted for 65% of total revenue for the first half of 2026. However, this growth was partially offset by lower realized prices. The company reported a gross margin of 85.8% for the second quarter, an increase from 84.3% in the prior year, attributed to improved production costs and a favorable product mix. Research and development expenses rose by 14% for the quarter, reflecting continued investment in the company's product pipeline.

Eli Lilly has been active in expanding its product offerings and capabilities through acquisitions. In the first half of 2026, the company completed significant acquisitions, including Centessa Pharmaceuticals and Kelonia Therapeutics, which contributed to a total of $13.3 billion spent on business development activities. The company also announced plans to acquire additional firms to bolster its infectious disease portfolio, with a total potential investment of up to $3.9 billion. As of June 30, 2026, Eli Lilly's total debt increased to $54.9 billion, up from $42.5 billion at the end of 2025, largely due to financing these acquisitions.

Operationally, Eli Lilly reported a total of 941.36 million shares outstanding as of August 3, 2026. The company has also been focusing on geographic expansion, with notable revenue increases in international markets, particularly in China and Europe, where revenue grew by 80% and 81%, respectively, compared to the previous year. The company continues to face challenges related to pricing pressures and regulatory scrutiny, particularly concerning its agreements with the U.S. government regarding drug pricing.

Looking ahead, Eli Lilly anticipates that its cardiometabolic health products will continue to represent a significant portion of its business. The company is also preparing for the potential impact of new regulatory approvals and market dynamics, particularly for its incretin products. The ongoing development of its product pipeline and strategic acquisitions are expected to play a crucial role in sustaining growth and maintaining competitive positioning in the pharmaceutical market.

About ELI LILLY & Co

Eli Lilly and Company is a global pharmaceutical firm focused on discovering, developing, manufacturing, and marketing human medicines. Its core segments include cardiometabolic health, oncology, immunology, and neuroscience, offering products like insulin, diabetes treatments, cancer therapies, and immunomodulators. Serving worldwide markets, Lilly emphasizes innovation, intellectual property protection, and strategic collaborations to deliver value-driven, effective therapies for diverse patient needs.

This description was generated via AI from an annual report. Updated about 1 year ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.

View the complete official filing on the SEC website.

Read on SEC.gov